Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
admin 12th June 2019 Uncategorised 0The path to success for Eli Lilly and Incyte’s rheumatoid arthritis drug Olumiant in the U.S. has been a precarious one, with the FDA repeatedly knocking the drug’s larger dose. Could new long-term safety data—and a potential label expansion—help turn the tide?
More: Look here, FDA: Eli Lilly touts Olumiant safety data for unapproved high dose
Source: fierce